ChemSpider 2D Image | Carfilzomib | C40H57N5O7

Carfilzomib

  • Molecular FormulaC40H57N5O7
  • Average mass719.910 Da
  • Monoisotopic mass719.425781 Da
  • ChemSpider ID9731489
  • defined stereocentres - 5 of 5 defined stereocentres


More details:



Featured data source



Validated by Experts, Validated by Users, Non-Validated, Removed by Users

72X6E3J5AR
868540-17-4 [RN]
8859
carfilzomib [Spanish] [INN]
carfilzomib [French] [INN]
carfilzomibum [Latin] [INN]
Kyprolis [Trade name]
L-Phenylalaninamide, N-[(2S)-2-[[2-(4-morpholinyl)acetyl]amino]-1-oxo-4-phenylbutyl]-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- [ACD/Index Name]
N-[(2S)-2-{[2-(4-Morpholinyl)acétyl]amino}-4-phénylbutanoyl]-L-leucyl-N-{(2S)-4-méthyl-1-[(2R)-2-méthyl-2-oxiranyl]-1-oxo-2-pentanyl}-L-phénylalaninamide [French] [ACD/IUPAC Name]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

PR-171 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Safety:

      L01XX45 Wikidata Q15366934
    • Chemical Class:

      A synthetic tetrapeptide consisting of morpholin-4-acetyl, <stereo>L</stereo>-2-amino-4-phenylbutanoyl, <stereo>L</stereo>-leucyl and <stereo>L</stereo>-phenylalanyl residues joined in sequence with t he C-terminus connected to the amino group of (2<element>S</element>)-2-amino-4-methyl-1-[(2<stereo>R</stereo>)-2-methyloxiran-2-yl]-1-oxopentan-1-one via an amide linkage. Used for the treatment of p atients with multiple myeloma ChEBI CHEBI:65347
    • Bio Activity:

      Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM. MedChem Express
      Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM.; IC50: < 5 nM [1]; Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant anti-tumor activity in patients with relapsed and refractory multiple myeloma (MM). MedChem Express HY-10455
      Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM.;IC50: < 5 nM [1]Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant anti-tumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 min, was evaluated in patients with solid tumors or MM. The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). Carfilzomib induced a dose- and time-dependent inhibition of proliferation, ultimately leading to apoptosis. Carfilzomib showed increased efficacy compared with bortezomib and was active against bortezomib-resistant MM cell lines and samples from patients with clinical bortezomib resistance. Carfi MedChem Express HY-10455
      Metabolism/Protease MedChem Express HY-10455
      Metabolism/Protease; MedChem Express HY-10455
      Proteasome MedChem Express HY-10455

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

Density: 1.2±0.1 g/cm3
Boiling Point: 975.6±65.0 °C at 760 mmHg
Vapour Pressure: 0.0±0.3 mmHg at 25°C
Enthalpy of Vaporization: 142.3±3.0 kJ/mol
Flash Point: 543.8±34.3 °C
Index of Refraction: 1.551
Molar Refractivity: 197.5±0.3 cm3
#H bond acceptors: 12
#H bond donors: 4
#Freely Rotating Bonds: 20
#Rule of 5 Violations: 3
ACD/LogP: 6.71
ACD/LogD (pH 5.5): 4.43
ACD/BCF (pH 5.5): 1256.10
ACD/KOC (pH 5.5): 5186.88
ACD/LogD (pH 7.4): 4.59
ACD/BCF (pH 7.4): 1794.35
ACD/KOC (pH 7.4): 7409.50
Polar Surface Area: 158 Å2
Polarizability: 78.3±0.5 10-24cm3
Surface Tension: 48.0±3.0 dyne/cm
Molar Volume: 619.6±3.0 cm3

Click to predict properties on the Chemicalize site





Feedback Form